SCHEMBL1521130

SCHEMBL1521130

COC(=O)c1ccc(-c2ccc(Cl)cc2CON)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.46
NLRP3 Q96P20 2/20 0.46
EGFR P00533 2/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
FFAR1 O14842 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
IDO1 P14902 2/20 0.42
MAPT P10636 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CA7 P43166 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14686222 0.86 EGFR (0.50) MAP2K4NLRP3EGFRMEN1KMT2A
SCHEMBL1520724 0.81 IDO1 (0.56) FFAR1FFAR4IDO1
SCHEMBL1520777 0.79 IDO1 (0.47) NLRP3MEN1KMT2AFFAR1FFAR4
SCHEMBL4300304 0.79 SRD5A2 (0.60) MAP2K4EGFRMEN1KMT2ASLC6A4
SCHEMBL792000 0.78 MAP4K4 (0.45) FFAR1FFAR4SLC6A4SLC6A3MAPT
SCHEMBL6824658 0.78 SLC6A4 (0.45) MAP2K4EGFRMEN1KMT2ASLC6A4
SCHEMBL792051 0.77 SRD5A2 (0.55) EGFRFFAR1FFAR4NPC1RAB9A
SCHEMBL12863740 0.76 ABL1 (0.54) MAP2K4EGFRMEN1KMT2ASLC6A4
SCHEMBL26115204 0.76 EGFR (0.51) MAP2K4EGFRMEN1KMT2ASLC6A4
SCHEMBL4707492 0.76 SLC6A4 (0.48) MAP2K4EGFRMEN1KMT2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227233-B1 IDO INHIBITORS NEWLINK GENETICS (US) 2013-02-13 EP claimed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US claimed
EP-2227233-A2 IDO INHIBITORS Newlink Genetics (US) 2010-09-15 EP claimed
WO-2009073620-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-06-11 WO claimed
WO-2019051198-A1 PRODRUG INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2019-03-14 WO disclosed
US-20130289083-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION 2013-10-31 US disclosed
EP-2227233-B1 IDO INHIBITORS NEWLINK GENETICS (US) 2013-02-13 EP disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053941-A1 IDO Inhibitors IDO1, IDO2, INMT MAP2K4 1626/4885NLRP3 2377/4885EGFR 2400/4885
US-20130289083-A1 IDO Inhibitors IDO1, IDO2, INMT MAP2K4 1774/4885NLRP3 2210/4885EGFR 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.